1 Jul 2008 07:05
1 July 2008
Plethora Solutions Holdings plc
("Plethora" or "the Company")
Share Options Award
Plethora Solutions Holdings PLC (AIM:PLE), the specialist developer of products for the treatment and management of urological disorders today announces the following arrangement with respect to share options ("Options") awarded to Directors and other employees.
On 25 June 2008, the Company's Remuneration Committee (which is comprised wholly of non-executive directors) awarded 582,459 Options to certain directors, being the Chief Executive Officer, Dr Steven Powell, the Chief Scientific Officer, Dr Michael Wyllie and CFO Designate, David Ellam, on his joining the Company and 515,069 to other employees, under the Company's Executive Share Option Scheme ("the Option Scheme"). These awards were part of the annual, company-wide performance-based remuneration review.
The exercise price for each Option will be 59p per ordinary share of 1p each in the capital of the Company ("Ordinary Shares"), with the Options being exercisable between the third and tenth anniversaries of the date the Options were granted. No consideration was paid for the grant of Options under the Option Scheme.
Details of the Options awarded to directors are as follows:
| Name | Options Issued | Total Number of Ordinary Shares over which Options are held following the Award |
| Steven J Powell | 120,983 | 1,334,951 |
| Michael G Wyllie | 111,476 | 724,491 |
| David J Ellam | 350,000 | 350,000 |
Enquiries:
| Plethora Solutions Steven Powell | Tel : +44(0) 20 3077 5400 |
| FinnCap (Nominated Advisor) Geoff Nash | Tel : +44(0) 20 7600 1658 |
| Hansard Group Adam Reynolds/John Bick | Tel: +44(0) 20 7245 1100 |
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder, stress urinary incontinence, interstitial cystitis, gynaecological pain, erectile dysfunction and premature ejaculation. In January 2006, Plethora acquired Minneapolis (Mn) based Timm Medical Technologies Inc., which markets products for the treatment of erectile dysfunction (ED) to urology clinics through a US-based specialty sales team. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE)
Further information is available at www.plethorasolutions.co.uk